2 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow X-Linked Adrenoleukodystrophy: new trials by email Literature Review of X-Linked Adrenoleukodystrophy trials Research Report on X-Linked Adrenoleukodystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Sobetirome (NV1205) - X-Linked Adrenoleukodystrophy | Phase 1 / Phase 2 | Withdrawn | NeuroVia, Inc. | 2018-08-01 | 2019-03-07 | |
| Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Sobetirome - X-Linked Adrenoleukodystrophy, Adrenomyeloneuropathy | Phase 1 | Withdrawn | Thomas S. Scanlan | 2013-04-01 | 2014-02-14 |
Adrenoleukodystrophy (2) · Thyroid Diseases (1)
Adrenal Gland Diseases (2) · Adrenal Insufficiency (2) · Brain Diseases (2) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Demyelinating Diseases (2) · Endocrine System Diseases (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Hereditary Central Nervous System Demyelinating Diseases (2) · Heredodegenerative Disorders, Nervous System (2) · Intellectual Disability (2) · Leukoencephalopathies (2)
GC 1 compound (2)
NeuroVia, Inc. (1) · Thomas S. Scanlan (1)
Argentina (1) · Australia (1) · Chile (1) · Colombia (1) · France (1) · Russia (1) · Ukraine (1) · United Kingdom (1) · United States (1)
David Koeller, MD (1) · John Henderson, MD (1)